International Journal of Molecular Sciences (Sep 2022)

Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection

  • Sara Lonardi,
  • Halla Nimeiri,
  • Chang Xu,
  • Daniel R. Zollinger,
  • Russell W. Madison,
  • Alexander D. Fine,
  • Ole Gjoerup,
  • Cosimo Rasola,
  • Valentina Angerilli,
  • Shruti Sharma,
  • Hsin-Ta Wu,
  • Charuta C. Palsuledesai,
  • Meenakshi Malhotra,
  • Alexey Aleshin,
  • Fotios Loupakis,
  • Elise Renkonen,
  • Priti Hegde,
  • Matteo Fassan

DOI
https://doi.org/10.3390/ijms231911529
Journal volume & issue
Vol. 23, no. 19
p. 11529

Abstract

Read online

A majority of patients with metastatic colorectal cancer (mCRC) experience recurrence post curative-intent surgery. The addition of adjuvant chemotherapy has shown to provide limited survival benefits when applied to all patients. Therefore, a biomarker to assess molecular residual disease (MRD) accurately and guide treatment selection is highly desirable for high-risk patients. This feasibility study evaluated the prognostic value of a tissue comprehensive genomic profiling (CGP)-informed, personalized circulating tumor DNA (ctDNA) assay (FoundationOne®Tracker) (Foundation Medicine, Inc., Cambridge, MA, USA) by correlating MRD status with clinical outcomes. ctDNA analysis was performed retrospectively on plasma samples from 69 patients with resected mCRC obtained at the MRD and the follow-up time point. Tissue CGP identified potentially actionable alterations in 54% (37/69) of patients. MRD-positivity was significantly associated with lower disease-free survival (DFS) (HR: 4.97, 95% CI: 2.67–9.24, p p p p < 0.0001). The overall sensitivity and specificity at the follow-up time point were 69% and 100%, respectively. Our results indicate that MRD detection using the tissue CGP-informed ctDNA assay is prognostic of survival outcomes in patients with resected mCRC. The concurrent MRD detection and identification of actionable alterations has the potential to guide perioperative clinical decision-making.

Keywords